key: cord-0274907-0ngbxbyd
authors: Palakkott, Abdulrasheed; Alneyadi, Aysha; Muhammad, Khalid; Eid, Ali H.; Amiri, Khaled; Ayoub, Mohammed Akli; Iratni, Rabah
title: The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling
date: 2022-05-12
journal: bioRxiv
DOI: 10.1101/2022.05.10.491351
sha: 8b28efcaea80590a7b702b9444bb252c46fb9dbb
doc_id: 274907
cord_uid: 0ngbxbyd

Objectives The coronavirus disease-19 (COVID-19) pandemic is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At the molecular and cellular levels, the SARS-Cov-2 uses its envelope glycoprotein, the spike S protein, to infect the target cells in the lungs via binding with their transmembrane receptor, the angiotensin-converting enzyme 2 (ACE2). Here, we wanted to invesitgate if other molecular targets and pathways may be used by SARS-Cov-2. Methods We investigated the possibility for the spike 1 S protein and its receptor-binding domain (RBD) to target the epidermal growth factor receptor (EGFR) and its downstream signaling pathway in vitro using the lung cancer cell line (A549 cells). Protein expression and phosphorylation was examined upon cell treatment with the recombinant full spike 1 S protein or RBD. Results We demonstrate for the first time the activation of EGFR by the Spike 1 protein associated with the phosphorylation of the canonical ERK1/2 and AKT kinases and an increase of survivin expression controlling the survival pathway. Conclusions Our study suggests the putative implication of EGFR and its related signaling pathways in SARS-CoV-2 infectivity and Covid-19 pathology. This may open new perspectives in the treatment of Covid-19 patients by targeting EGFR.

metallopeptidase with the catalytic site oriented extracellularly is mostly expressed in 60 lung, heart, kidney, brain, and gut. In contrast to ACE which converts angiotensin I to 61 the active vasoconstrictor, angiotensin II (AngII), ACE2 breaks down AngII to 62 angiotensin-(1-9 and 1-7), which are potent vasodilators, and considered as a negative 63 regulator of RAS (Lavoie & Sigmund, 2003) . The implication of ACE2 in COVID-19 is Although large body of evidence using in vitro studies and in silico data strongly support 105 the thesis that ACE2 is necessary for SARS-CoV-2 entry, still, we cannot rule out that 106 additional factors and/or alternative cell surface receptors may be also implicated in we hypothesize that during SARS-CoV-2 infectivity, the virus may also use EGFR 116 expressed on the epithelial lung cells as the receptor/co-receptor target for its entry. protein assay kit (Thermo Scientific) and the lysates were adjusted with lysis buffer. 146

Aliquots of 25 µg of total cell lysate were resolved onto 6-15% SDS-PAGE. Proteins 147 were transferred to nitrocellulose membranes (Thermo Scientific) and blocked for 1 h at 148 room temperature with 5% non-fat dry milk in TBST (TBS and 0.05% Tween 20). 149

Incubation with specific primary antibodies was performed in blocking buffer overnight at 150 4ºC and this was true for all the primary protein antibodies used in this study. Notice that 151 all the lysates were freshly loaded when different phospho-proteins were analyzed. 152

However, the same membrane of the phospho-protein was stripped to examine the 153 corresponding total protein loaded except for pERK1/2 where the proteins were always 154 freshly loaded due to stronger anti-pERK1/2 binding. Moreover, a 

First, we examined the effect of Spike 1 and RBD on the phosphorylation status of 164 EGFR and its related kinases, AKT and ERK1/2, in lung cancer cells (A549) (Figure 1) . 165

The treatment of cells for 5 minutes with Spike (2.5 μg/ml) promoted a strong 166 phosphorylation of EGFR, AKT, and ERK1/2, which was either similar (EGFR and 167 ERK1/2) or even higher (AKT) to that promoted by stimulation with the maximal dose of 168 EGF (5 μg/ml) (Figure 1) . On the other hand, RBD (5 μg/ml) under a similar condition 169

showed almost no effect on EGFR phosphorylation while it significantly induced AKT 170 and ERK1/2 phosphorylation (Figure 1) . This result suggests the specific targeting of 171 EGFR by the full spike 1 protein of SARS-COV-2 but not by its RBD. Also, our data 172 suggest that RBD-mediated AKT and ERK1/2 activation is independent on EGFR 173 activation and that other molecular targets and/or intracellular mechanisms may be 174

We next performed time-course analysis with both Spike 1 and RBD on the 176 phosphorylation status of EGFR and ERK1/2. For this, A549 cells were treated with 177

Spike 1 (2.5 μg/ml) (Figure 2A) or RBD (5 μg/ml) ( Figure 2B) for 5, 15, 30, and 60 178 minutes. Stimulation with EGF (5 μg/ml) as a positive control was carried out for 15 179 minutes. As shown in Figure 2A , Spike 1 induced a rapid and a transient 180 phosphorylation of EGFR and ERK1/2 with a pic at 5 minutes of stimulation and sharp 181 decrease after 15 minutes. Spike 1-mediated AKT activation, on the other hand, was 182 also observed upon 5 minutes of stimulation but this was more sustained in time 183 (Figure 2A) . For RBD, there was no clear EGFR phosphorylation induced regardless of 184 the stimulation time ( Figure 2B) . This is consistent with our observation in Figure 1B . 185

However, RBD promoted rapid and strong activation of both ERK1/2 and AKT that 186 remained persistent even after 60 minutes of stimulation ( Figure 2B) . 187

Together, these data further confirm the specific activation of EGFR by Spike 1, but not 188 RBD, but they also demonstrate the implication of additional and/or different 189 mechanisms in AKT and ERK1/2 activation whether cells were activated by Spike 1 or 190

Next, we decided to further explore the targeting of EGFR and its related downstream 194 AKT survival pathway by Spike 1 and RBD by using the selective EGFR antagonist, 195 Figure 3A , the pre-treatment of A549 cells with AG1478 (10 μM) 196 fully blocked EGFR phosphorylation induced by stimulation with EGF (5 μg/ml) 197

indicating the specificity of the response. We found that, AG1478 completed abolished 198 AKT phosphorylation induced by EGF, Spike 1, or RBD ( Figure 3B ). This finding 199 strongly suggests that Spike 1-and RBD-mediated AKT phosphorylation is dependent 200 on EGFR activation. 201 202

Since EGFR, AKT, and ERK1/2 pathways are known for their role in cell proliferation 204 and cell survival, we wanted to link our data on the phosphorylation status of these 205 proteins especially EGFR and AKT with the induction of the anti-apoptotic protein, 206 survivin, which belongs to the inhibitor of apoptosis (IAP) family and considered as the 207 key marker for the activation of the survival pathway in cells. Moreover, the activation of 208 survivin was shown to be induced by both AKT and ERK1/2 signaling in cells. For this, 209 we wanted to test whether Spike-and RBD-mediated activation of ERK1/2 and AKT 210 was associated with the induction of surviving expression. Toward this, A549 cells were 211 treated with Spike 1 (2.5 μg/ml) (Figure 4A ) or RBD (5 μg/ml) (Figure 4B) The authors declare no ethical approval was needed for this study. 

Determinants of the outcomes of patients with cancer 303 infected with SARS-CoV-2: results from the Gustave Roussy cohort

Meningococcus Hijacks a β 2-adrenoceptor/β-308

Arrestin pathway to cross brain microvasculature endothelium

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A 313

Multicenter Study during the COVID-19 Outbreak

Coronavirus Disease 2019 (COVID-19) and Cardiovascular 317 Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme 318

Respiratory Syndrome Coronavirus 2 Infection

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

327 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 328 Clinically Proven Protease Inhibitor

Characteristics of SARS-CoV-2 and COVID-19

SARS-CoV-2 vaccines in development

Minireview: overview of the renin-angiotensin system--an 338 endocrine and paracrine system

Role of specialized pro-resolving lipid mediators and their receptors in virus 342 infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm

Angiotensin-converting enzyme 2 347 is a functional receptor for the SARS coronavirus

Renin-Angiotensin System and Coronavirus Disease 2019: A 352 Narrative Review

The 356 Role of EGFR in Influenza Pathogenicity: Multiple Network-Based Approaches to 357 Identify a Key Regulator of Non-lethal Infections

Interaction between RAAS inhibitors and ACE2 in the context of 361 COVID-19

Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors

Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during 366 Hospitalizations for Acute Heart Failure

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and 370

Angiotensin Receptor Blockers: What Is the Evidence?

Comprehending a Killer: The Akt/mTOR 374

Signaling Pathways Are Temporally High-Jacked by the Highly Pathogenic

Viral hijacking of G-protein-coupled-receptor signalling 378 networks

Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor

Blockers Have a Biphasic Effect?

Controversies of renin-386 angiotensin system inhibition during the COVID-19 pandemic

Targeting the renin-angiotensin signaling pathway in 390 COVID-19: Unanswered questions, opportunities, and challenges

Inflammation and thrombosis in COVID-19 pathophysiology

Proteinase-activated and purinergic receptors as drivers and candidate therapeutic 395 targets

Characterization of the 398 receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development 399 of RBD protein as a viral attachment inhibitor and vaccine

COVID-19 403 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking 404 at a potential treatment

The role of epidermal growth factor receptor (EGFR) 407 signaling in SARS coronavirus-induced pulmonary fibrosis

A novel coronavirus outbreak of global 411 health concern

Identification of the epidermal growth factor 415 receptor as the receptor for Salmonella Rck-dependent invasion

Structural basis for the recognition of 419 SARS-CoV-2 by full-length human ACE2

ACE2: Evidence of role as entry receptor for 423 SARS-CoV-2 and implications in comorbidities. eLife (2020) 9:e61390

Hijacking GPCRs by viral pathogens and tumor

A Novel Coronavirus from 431 Patients with Pneumonia in China